Skip to main content Back to Top
Advertisement

3/20/2024

Lisdexamfetamine Dimesylate Capsules

Products Affected - Description

    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 10 mg, bottle, 100 count, NDC 47781-0562-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 20 mg, bottle, 100 count, NDC 47781-0563-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 30 mg, bottle, 100 count, NDC 47781-0564-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 40 mg, bottle, 100 count, NDC 47781-0565-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 50 mg, bottle, 100 count, NDC 47781-0566-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 60 mg, bottle, 100 count, NDC 47781-0567-01
    • Lisdexamfetamine dimesylate oral capsule, Alvogen, 70 mg, bottle, 100 count, NDC 47781-0568-01
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 20 mg, bottle, 90 count, NDC 65162-0023-09
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 30 mg, bottle, 90 count, NDC 65162-0024-09
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 40 mg, bottle, 90 count, NDC 65162-0025-09
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 50 mg, bottle, 90 count, NDC 65162-0026-09
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 60 mg, bottle, 90 count, NDC 65162-0027-09
    • Lisdexamfetamine dimesylate oral capsule, Amneal, 70 mg, bottle, 90 count, NDC 65162-0028-09
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 20 mg, bottle, 100 count, NDC 00054-0370-25
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 30 mg, bottle, 100 count, NDC 00054-0371-25
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 40 mg, bottle, 100 count, NDC 00054-0372-25
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 50 mg, bottle, 100 count, NDC 00054-0373-25
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 60 mg, bottle, 100 count, NDC 00054-0374-25
    • Lisdexamfetamine dimesylate oral capsule, Hikma, 70 mg, bottle, 100 count, NDC 00054-0375-25
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 10 mg, bottle, 100 count, NDC 00527-4661-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 20 mg, bottle, 100 count, NDC 00527-4662-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 30 mg, bottle, 100 count, NDC 00527-4663-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 40 mg, bottle, 100 count, NDC 00527-4664-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 50 mg, bottle, 100 count, NDC 00527-4665-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 60 mg, bottle, 100 count, NDC 00527-4666-37
    • Lisdexamfetamine dimesylate oral capsule, Lannett, 70 mg, bottle, 100 count, NDC 00527-4667-37
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 10 mg, bottle, 90 count, NDC 00378-6854-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 20 mg, bottle, 90 count, NDC 00378-6855-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 30 mg, bottle, 90 count, NDC 00378-6856-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 40 mg, bottle, 90 count, NDC 00378-6857-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 50 mg, bottle, 90 count, NDC 00378-6858-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 60 mg, bottle, 90 count, NDC 00378-6859-77
    • Lisdexamfetamine dimesylate oral capsule, Mylan (Viatris), 70 mg, bottle, 90 count, NDC 00378-6860-77
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 10 mg, bottle, 100 count, NDC 42858-0161-01
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 20 mg, bottle, 100 count, NDC 42858-0162-01
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 10 mg, bottle, 100 count, NDC 43547-0602-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 20 mg, bottle, 100 count, NDC 43547-0603-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 30 mg, bottle, 100 count, NDC 43547-0604-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 40 mg, bottle, 100 count, NDC 43547-0605-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 50 mg, bottle, 100 count, NDC 43547-0606-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 60 mg, bottle, 100 count, NDC 43547-0607-10
    • Lisdexamfetamine dimesylate oral capsule, Solco Healthcare US, 70 mg, bottle, 100 count, NDC 43547-0608-10
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 10 mg, bottle, 100 count, NDC 57664-0046-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 20 mg, bottle, 100 count, NDC 57664-0047-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 30 mg, bottle, 100 count, NDC 57664-0048-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 40 mg, bottle, 100 count, NDC 57664-0049-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 50 mg, bottle, 100 count, NDC 57664-0050-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 60 mg, bottle, 100 count, NDC 57664-0051-88
    • Lisdexamfetamine dimesylate oral capsule, Sun Pharma, 70 mg, bottle, 100 count, NDC 57664-0052-88

Reason for the Shortage

    • Alvogen has lisdexamfetamine capsules on shortage due to regulatory delays.
    • Amneal has lisdexamfetamine capsules on shortage due to an issue with the active ingredient.
    • Hikma has lisdexamfetamine capsules on shortage due to an issue with the active ingredient.
    • Lannett did not provide a reason for the shortage.
    • Mallinckrodt does not provide information on drug shortages.
    • Mylan has lisdexamfetamine capsules available.
    • Rhodes launched lisdexamfetamine 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules in March 2024. The 10 mg and 20 mg capsules have not been launched and the company cannot estimate a release date.
    • Solco has lisdexamfetamine capsules on shortage due to an issue with the active ingredient.
    • Sun Pharma has lisdexamfetamine capsules on shortage due to regulatory delays.
    • Takeda has Vyvanse available.

Available Products

    • Vyvanse oral capsule, Takeda, 10 mg, bottle, 100 count, NDC 59417-0101-10
    • Vyvanse oral capsule, Takeda, 20 mg, bottle, 100 count, NDC 59417-0102-10
    • Vyvanse oral capsule, Takeda, 30 mg, bottle, 100 count, NDC 59417-0103-10
    • Vyvanse oral capsule, Takeda, 40 mg, bottle, 100 count, NDC 59417-0104-10
    • Vyvanse oral capsule, Takeda, 50 mg, bottle, 100 count, NDC 59417-0105-10
    • Vyvanse oral capsule, Takeda, 60 mg, bottle, 100 count, NDC 59417-0106-10
    • Vyvanse oral capsule, Takeda, 70 mg, bottle, 100 count, NDC 59417-0107-10
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 30 mg, bottle, 100 count, NDC 42858-0163-01
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 40 mg, bottle, 100 count, NDC 42858-0164-01
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 50 mg, bottle, 100 count, NDC 42858-0165-01
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 60 mg, bottle, 100 count, NDC 42858-0166-01
    • Lisdexamfetamine dimesylate oral capsule, Rhodes, 70 mg, bottle, 100 count, NDC 42858-0167-01

Estimated Resupply Dates

    • Alvogen has lisdexamfetamine 30 mg, 60 mg, and 70 mg capsules in limited supply. All other presentations are on back order and the company cannot estimate a release date.
    • Amneal has lisdexamfetamine capsules on back order and the company cannot estimate a release date.
    • Hikma has lisdexamfetamine capsules on allocation.
    • Lannett has lisdexamfetamine 10 mg and 20 mg capsules on allocation. All other presentations are on back order and the company cannot estimate a release date.
    • Mylan has lisdexamfetamine capsules on allocation.
    • Solco has lisdexamfetamine capsules on allocation.
    • Sun Pharma has all presentations on back order and the company estimates additional product will be available in May to June 2024.

Alternative Agents & Management

    • Vyvanse chewable tablets are not affected by this shortage.

Updated

Updated March 20, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 19, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT